In August, 65.2% of patients on England's NHS waiting list had waited up to 18 weeks, 4.2 points better than a year earlier.1 Most of that gain came in a single month, and the share has barely moved since.
NHS England published its August referral-to-treatment figures on 8 October. Of about 7.4 million waiting pathways, 65.2% had been waiting up to 18 weeks.1 The standard is 92%. Reaching it would put roughly two million more of those pathways inside 18 weeks.
The year-on-year gain is real, but its shape matters. Between April 2025 and February 2026 the share crept up by 2.9 points, from 59.7% to 62.6%. It then jumped to 65.3% in March 2026 and has stayed between 65.0% and 65.8% in each of the six months since.1 Over those six months it is down 0.1 of a point. A year earlier, March to August added 1.2 points.1
In the March snapshots in the same table, the share was above 92% in each year from 2012 to 2015, ending at 92.9% in March 2015. It was 86.3% in March 2019, fell to 64.4% in March 2021 and reached a low of 57.2% in March 2024.1 The figure for March 2026 is the highest March figure since 2020, but is still about 21 points below March 2019. The table publishes only March values for these years, so months in between are not shown.
Performance varies by specialty. In August, 53.8% of oral surgery pathways and 56.8% of ear, nose and throat pathways were within 18 weeks, against 72.2% in ophthalmology.1 Trauma and orthopaedics, the largest list at 843,419 pathways, stood at 61.1%.1
The median wait of those still waiting was 12.2 weeks in August, down from 13.5 weeks a year earlier. The 92nd-percentile wait was 38.8 weeks, down from 42.2.1 The list itself is almost unchanged: it was 0.5% (33,512 pathways) smaller than in August 2025.1 The long waits remain: 10,782 pathways had waited more than 65 weeks, 1,637 more than 78 weeks and 222 more than 104 weeks.1 The desk covered the size of the list over a longer run in an earlier piece.
The figures say nothing about why the share jumped in March. It coincided with the end of the financial year, and one reading is that effort was concentrated before that date; the data cannot confirm this. Six months is a short run, so a plateau is a description, not a forecast: the share could resume rising. Four trusts submitted no August data, and their numbers are estimated from earlier returns, one of them from June 2025.1 The median and 92nd-percentile waits exclude those estimates.